The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Share News (SAR)

Share Price Information for Sareum (SAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.75
Bid: 41.00
Ask: 42.50
Change: 5.25 (14.38%)
Spread: 1.50 (3.659%)
Open: 37.00
High: 42.50
Low: 36.00
Prev. Close: 36.50
SAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: LungLife AI soars on test; Plexus falls on deal

Tue, 02nd Jan 2024 10:05

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

----------

AIM - WINNERS

----------

LungLife AI Inc, up 36% at 62.33 pence, 12-month range 19.00p-141.10p. The developer of clinical diagnostic solutions designed to address the early detection of lung cancer announces the successful validation of its LungLB test for indeterminate lung nodules. This is from a "prospective, multi-site clinical study in the clinically important small nodules patient group". The LungLB test is a blood-based tool used by clinicians to help with earlier diagnosis of lung cancer nodules. The diagnostic demonstrates a positive predictive value of 81% in distinguishing benign from cancerous lung nodules in patients with nodules smaller than 15 millimetres. This surpasses the current clinical standard of around 60%. According to LungLife, the results are sufficient for publication and the execution of its commercial programme for LungLB. The initial launch will be through an early access program offered from its California laboratory in the first quarter of 2024.

----------

Sareum Holdings PLC, up 19% at 71.00p, 12-month range 50.00p-149.00p. The pharmaceutical company's co-development partner CRT Pioneer Fund enters into a development and commercialisation licence for SRA737 with an unnamed US biopharmaceutical company. SRA737 is a clinical-stage oral, selective checkpoint kinase 1 inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Sareum says an immediate upfront payment of USD500,000 is due to CRT Pioneer Fund, while an additional fee made up of up to USD1.0 million cash and 500,000 shares in the licensee company may be payable upon the sooner 12 months following the signing of the licencing agreement, or if the licensee company achieves certain commercial and material financing objectives. A further announcement regarding any future income, including any shares which may be issued, will be made "at the appropriate time".

----------

AIM - LOSERS

----------

Plexus Holdings PLC, down 15% at 17.94p, 12-month range 1.60p-31.40p. The oil and gas engineering services business completes an agreement with SLB to replace an existing surface production wellhead licence with a new licence over a wider field of use for USD5.2 million in cash. It says SLB acquires a perpetual royalty free license for Pos-Grip technology and HG seal technology plus any improvements, enhancements, or derivatives to the technology for surface wellhead production applications for all pressure and size ranges. Plexus says the licence scope includes oil and gas production and storage applications, as well as carbon dioxide storage and hydrogen storage, alongside water and cuttings reinjection. Plexus Chief Executive Officer Ben van Bilderbeek says: "This new licence agreement is a further validation of Plexus' [intellectual property] by this leading energy technology company and recognises the contribution our leak-proof POS-GRIP wellhead equipment can make to the oil and gas industry's [environmental, social and governance] and net zero goals."

----------

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
10 Mar 2016 13:00

Sareum Holdings Unaware Of Reason For Share Price Jump

Read more
24 Feb 2016 12:25

Sareum inches closer to drug breakthrough

(ShareCast News) - Sareum Holdings was still running on the smell of an oily rag in its interim report on Wednesday, but the company was confident it was heading towards a breakthrough in its durgs under development. The AIM-traded cancer drug discovery and development business saw no revenue during

Read more
24 Feb 2016 09:40

Sareum Holdings Reports Narrowed Loss As It Focuses On CHK1 Trials

Read more
1 Feb 2016 09:14

Sareum Submits Clinical Trial Applications For Cancer Drug Candidate

Read more
15 Dec 2015 08:40

Sareum Clinical Trials Application For Cancer Drug Coming In January

Read more
8 Dec 2015 15:58

AGM, EGM Calendar - Week Ahead

Read more
26 Oct 2015 08:59

Sareum Holdings Loss Widens As It Moves Towards Clinical Trials

Read more
15 Sep 2015 08:06

Sareum Holdings Gets US, European Patents For Aurora+FLT3 Inhibitors

Read more
23 Jul 2015 09:06

Sareum Says Journal Reports On Lung And Pancreatic Cancer Treatment

Read more
17 Jun 2015 07:56

Sareum Wins Funding To Investigate Treatment Of Adolescent Leukaemia

Read more
28 May 2015 11:26

LONDON MIDDAY BRIEFING: Corporate Sponsors Join Backlash Against FIFA

Read more
28 May 2015 10:35

WINNERS & LOSERS: Sports Direct Expects Earnings To Beat Forecasts

Read more
28 May 2015 07:13

Sareum Raises GBP1.4 Million Via Discounted Share Placing (ALLISS)

Read more
12 May 2015 12:28

LONDON MIDDAY BRIEFING: EasyJet Outlook Hits Turbulence

Read more
12 May 2015 10:36

WINNERS & LOSERS: easyJet Slides As Analysts Set To Cut Forecasts

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.